Laboratory Monitoring of Biological Therapies in Rheumatology: The Role of Immunogenicity

Biological drugs, such as proteins and immunogens, are increasingly used to treat various diseases, including tumors and autoimmune diseases, and biological molecules have almost completely replaced synthetic drugs in rheumatology. Although biological treatments such as anti-tumor necrosis factor (T...

Full description

Saved in:
Bibliographic Details
Published in:Annals of laboratory medicine 2020, 40(2), , pp.101-113
Main Authors: Benucci, Maurizio, Grossi, Valentina, Manfredi, Mariangela, Damiani, Arianna, Infantino, Maria, Moscato, Paolo, Cinquanta, Luigi, Gremese, Elisa, Tolusso, Barbara, Petricca, Luca, Fedele, Anna Laura, Alivernini, Stefano, Atzeni, Fabiola, Minisola, Giovanni, Verna, Roberto
Format: Article
Language:English
Subjects:
Adalimumab - blood
Adalimumab - immunology
Adalimumab - therapeutic use
Antibodies, Monoclonal - blood
Antibodies, Monoclonal - immunology
Antibodies, Monoclonal - therapeutic use
Arthritis, Rheumatoid - drug therapy
Biological Factors - blood
Biological Factors - immunology
Biological Factors - therapeutic use
Biosimilar Pharmaceuticals - blood
Biosimilar Pharmaceuticals - therapeutic use
Drug Monitoring
Humans
Review
병리학
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c433t-47b772b348d1ae9c321c2b912f3ebcc56303e5e1236f95d597a293e3aab597753
cites cdi_FETCH-LOGICAL-c433t-47b772b348d1ae9c321c2b912f3ebcc56303e5e1236f95d597a293e3aab597753
container_end_page 113
container_issue 2
container_start_page 101
container_title Annals of laboratory medicine
container_volume 40
creator Benucci, Maurizio
Grossi, Valentina
Manfredi, Mariangela
Damiani, Arianna
Infantino, Maria
Moscato, Paolo
Cinquanta, Luigi
Gremese, Elisa
Tolusso, Barbara
Petricca, Luca
Fedele, Anna Laura
Alivernini, Stefano
Atzeni, Fabiola
Minisola, Giovanni
Verna, Roberto
description Biological drugs, such as proteins and immunogens, are increasingly used to treat various diseases, including tumors and autoimmune diseases, and biological molecules have almost completely replaced synthetic drugs in rheumatology. Although biological treatments such as anti-tumor necrosis factor (TNF) drugs seem to be quite safe, they cause some undesirable effects, such as the onset of infections due to weakening of the immune system. Given the biological nature of these drugs, they might be recognized as extraneous; this would induce an immune reaction that neutralizes their effectiveness or lead to more serious consequences. Laboratories play a pivotal role in appropriate therapeutic management. The aim of this review was to underline the production of anti-drug antibodies during treatment with biological drugs and highlight the role of laboratories in ensuring appropriate use of these drugs.
doi_str_mv 10.3343/alm.2020.40.2.101
format article
fullrecord <record><control><sourceid>proquest_nrf_k</sourceid><recordid>TN_cdi_nrf_kci_oai_kci_go_kr_ARTI_6867396</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2309481263</sourcerecordid><originalsourceid>FETCH-LOGICAL-c433t-47b772b348d1ae9c321c2b912f3ebcc56303e5e1236f95d597a293e3aab597753</originalsourceid><addsrcrecordid>eNpVUU2P0zAQtRCIXS37A7igHOHQYM84TsMBaVmxS6UipKocOFmOO2nNJnaxE6T-e9ztUsFc5snvwyM9xl4LXiJKfG_6oQQOvJS8hFJw8YxdAqCc4VzI52fM1QW7Tuknz6O4gIa_ZBcoVMVrUJfsx9K0IZoxxEPxNXiXgfPbInTFJxf6sHXW9MV6R9HsHaXC-WK1o2nIhkwePhypYhV6OjoWwzD5sCXvrBsPr9iLzvSJrp_2Fft-93l9-2W2_Ha_uL1ZzqxEHGeybusaWpTzjTDUWARhoW0EdEittZVCjlSRAFRdU22qpjbQIKExbcZ1hVfs3SnXx04_WKeDcY97G_RD1Der9UKruaqxUVn78aTdT-1AG0t-jKbX--gGEw-Pzv8Z73Y553cOAOCC54C3TwEx_JoojXpwyVLfG09hShqQN3IuQGGWipPUxpBSpO78jeD62KDODepjg1pyDflVZM-bf-87O_72hX8AdM6Xrw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2309481263</pqid></control><display><type>article</type><title>Laboratory Monitoring of Biological Therapies in Rheumatology: The Role of Immunogenicity</title><source>PubMed Central</source><creator>Benucci, Maurizio ; Grossi, Valentina ; Manfredi, Mariangela ; Damiani, Arianna ; Infantino, Maria ; Moscato, Paolo ; Cinquanta, Luigi ; Gremese, Elisa ; Tolusso, Barbara ; Petricca, Luca ; Fedele, Anna Laura ; Alivernini, Stefano ; Atzeni, Fabiola ; Minisola, Giovanni ; Verna, Roberto</creator><creatorcontrib>Benucci, Maurizio ; Grossi, Valentina ; Manfredi, Mariangela ; Damiani, Arianna ; Infantino, Maria ; Moscato, Paolo ; Cinquanta, Luigi ; Gremese, Elisa ; Tolusso, Barbara ; Petricca, Luca ; Fedele, Anna Laura ; Alivernini, Stefano ; Atzeni, Fabiola ; Minisola, Giovanni ; Verna, Roberto</creatorcontrib><description>Biological drugs, such as proteins and immunogens, are increasingly used to treat various diseases, including tumors and autoimmune diseases, and biological molecules have almost completely replaced synthetic drugs in rheumatology. Although biological treatments such as anti-tumor necrosis factor (TNF) drugs seem to be quite safe, they cause some undesirable effects, such as the onset of infections due to weakening of the immune system. Given the biological nature of these drugs, they might be recognized as extraneous; this would induce an immune reaction that neutralizes their effectiveness or lead to more serious consequences. Laboratories play a pivotal role in appropriate therapeutic management. The aim of this review was to underline the production of anti-drug antibodies during treatment with biological drugs and highlight the role of laboratories in ensuring appropriate use of these drugs.</description><identifier>ISSN: 2234-3806</identifier><identifier>EISSN: 2234-3814</identifier><identifier>DOI: 10.3343/alm.2020.40.2.101</identifier><identifier>PMID: 31650726</identifier><language>eng</language><publisher>Korea (South): The Korean Society for Laboratory Medicine</publisher><subject>Adalimumab - blood ; Adalimumab - immunology ; Adalimumab - therapeutic use ; Antibodies, Monoclonal - blood ; Antibodies, Monoclonal - immunology ; Antibodies, Monoclonal - therapeutic use ; Arthritis, Rheumatoid - drug therapy ; Biological Factors - blood ; Biological Factors - immunology ; Biological Factors - therapeutic use ; Biosimilar Pharmaceuticals - blood ; Biosimilar Pharmaceuticals - therapeutic use ; Drug Monitoring ; Humans ; Review ; 병리학</subject><ispartof>Annals of Laboratory Medicine, 2020, 40(2), , pp.101-113</ispartof><rights>The Korean Society for Laboratory Medicine.</rights><rights>The Korean Society for Laboratory Medicine 2020 The Korean Society for Laboratory Medicine</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c433t-47b772b348d1ae9c321c2b912f3ebcc56303e5e1236f95d597a293e3aab597753</citedby><cites>FETCH-LOGICAL-c433t-47b772b348d1ae9c321c2b912f3ebcc56303e5e1236f95d597a293e3aab597753</cites><orcidid>0000-0001-9148-1548 ; 0000-0001-8180-6660 ; 0000-0002-9108-6609 ; 0000-0003-3544-3162 ; 0000-0003-4702-7094 ; 0000-0001-6327-0874 ; 0000-0003-2817-4822 ; 0000-0002-8980-5141 ; 0000-0002-2287-3027 ; 0000-0001-9242-2793 ; 0000-0002-1869-3912 ; 0000-0002-7383-4212 ; 0000-0002-2248-1058 ; 0000-0002-9328-3075 ; 0000-0002-6200-4467</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822010/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822010/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31650726$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002558919$$DAccess content in National Research Foundation of Korea (NRF)$$Hfree_for_read</backlink></links><search><creatorcontrib>Benucci, Maurizio</creatorcontrib><creatorcontrib>Grossi, Valentina</creatorcontrib><creatorcontrib>Manfredi, Mariangela</creatorcontrib><creatorcontrib>Damiani, Arianna</creatorcontrib><creatorcontrib>Infantino, Maria</creatorcontrib><creatorcontrib>Moscato, Paolo</creatorcontrib><creatorcontrib>Cinquanta, Luigi</creatorcontrib><creatorcontrib>Gremese, Elisa</creatorcontrib><creatorcontrib>Tolusso, Barbara</creatorcontrib><creatorcontrib>Petricca, Luca</creatorcontrib><creatorcontrib>Fedele, Anna Laura</creatorcontrib><creatorcontrib>Alivernini, Stefano</creatorcontrib><creatorcontrib>Atzeni, Fabiola</creatorcontrib><creatorcontrib>Minisola, Giovanni</creatorcontrib><creatorcontrib>Verna, Roberto</creatorcontrib><title>Laboratory Monitoring of Biological Therapies in Rheumatology: The Role of Immunogenicity</title><title>Annals of laboratory medicine</title><addtitle>Ann Lab Med</addtitle><description>Biological drugs, such as proteins and immunogens, are increasingly used to treat various diseases, including tumors and autoimmune diseases, and biological molecules have almost completely replaced synthetic drugs in rheumatology. Although biological treatments such as anti-tumor necrosis factor (TNF) drugs seem to be quite safe, they cause some undesirable effects, such as the onset of infections due to weakening of the immune system. Given the biological nature of these drugs, they might be recognized as extraneous; this would induce an immune reaction that neutralizes their effectiveness or lead to more serious consequences. Laboratories play a pivotal role in appropriate therapeutic management. The aim of this review was to underline the production of anti-drug antibodies during treatment with biological drugs and highlight the role of laboratories in ensuring appropriate use of these drugs.</description><subject>Adalimumab - blood</subject><subject>Adalimumab - immunology</subject><subject>Adalimumab - therapeutic use</subject><subject>Antibodies, Monoclonal - blood</subject><subject>Antibodies, Monoclonal - immunology</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Biological Factors - blood</subject><subject>Biological Factors - immunology</subject><subject>Biological Factors - therapeutic use</subject><subject>Biosimilar Pharmaceuticals - blood</subject><subject>Biosimilar Pharmaceuticals - therapeutic use</subject><subject>Drug Monitoring</subject><subject>Humans</subject><subject>Review</subject><subject>병리학</subject><issn>2234-3806</issn><issn>2234-3814</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNpVUU2P0zAQtRCIXS37A7igHOHQYM84TsMBaVmxS6UipKocOFmOO2nNJnaxE6T-e9ztUsFc5snvwyM9xl4LXiJKfG_6oQQOvJS8hFJw8YxdAqCc4VzI52fM1QW7Tuknz6O4gIa_ZBcoVMVrUJfsx9K0IZoxxEPxNXiXgfPbInTFJxf6sHXW9MV6R9HsHaXC-WK1o2nIhkwePhypYhV6OjoWwzD5sCXvrBsPr9iLzvSJrp_2Fft-93l9-2W2_Ha_uL1ZzqxEHGeybusaWpTzjTDUWARhoW0EdEittZVCjlSRAFRdU22qpjbQIKExbcZ1hVfs3SnXx04_WKeDcY97G_RD1Der9UKruaqxUVn78aTdT-1AG0t-jKbX--gGEw-Pzv8Z73Y553cOAOCC54C3TwEx_JoojXpwyVLfG09hShqQN3IuQGGWipPUxpBSpO78jeD62KDODepjg1pyDflVZM-bf-87O_72hX8AdM6Xrw</recordid><startdate>20200301</startdate><enddate>20200301</enddate><creator>Benucci, Maurizio</creator><creator>Grossi, Valentina</creator><creator>Manfredi, Mariangela</creator><creator>Damiani, Arianna</creator><creator>Infantino, Maria</creator><creator>Moscato, Paolo</creator><creator>Cinquanta, Luigi</creator><creator>Gremese, Elisa</creator><creator>Tolusso, Barbara</creator><creator>Petricca, Luca</creator><creator>Fedele, Anna Laura</creator><creator>Alivernini, Stefano</creator><creator>Atzeni, Fabiola</creator><creator>Minisola, Giovanni</creator><creator>Verna, Roberto</creator><general>The Korean Society for Laboratory Medicine</general><general>대한진단검사의학회</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>ACYCR</scope><orcidid>https://orcid.org/0000-0001-9148-1548</orcidid><orcidid>https://orcid.org/0000-0001-8180-6660</orcidid><orcidid>https://orcid.org/0000-0002-9108-6609</orcidid><orcidid>https://orcid.org/0000-0003-3544-3162</orcidid><orcidid>https://orcid.org/0000-0003-4702-7094</orcidid><orcidid>https://orcid.org/0000-0001-6327-0874</orcidid><orcidid>https://orcid.org/0000-0003-2817-4822</orcidid><orcidid>https://orcid.org/0000-0002-8980-5141</orcidid><orcidid>https://orcid.org/0000-0002-2287-3027</orcidid><orcidid>https://orcid.org/0000-0001-9242-2793</orcidid><orcidid>https://orcid.org/0000-0002-1869-3912</orcidid><orcidid>https://orcid.org/0000-0002-7383-4212</orcidid><orcidid>https://orcid.org/0000-0002-2248-1058</orcidid><orcidid>https://orcid.org/0000-0002-9328-3075</orcidid><orcidid>https://orcid.org/0000-0002-6200-4467</orcidid></search><sort><creationdate>20200301</creationdate><title>Laboratory Monitoring of Biological Therapies in Rheumatology: The Role of Immunogenicity</title><author>Benucci, Maurizio ; Grossi, Valentina ; Manfredi, Mariangela ; Damiani, Arianna ; Infantino, Maria ; Moscato, Paolo ; Cinquanta, Luigi ; Gremese, Elisa ; Tolusso, Barbara ; Petricca, Luca ; Fedele, Anna Laura ; Alivernini, Stefano ; Atzeni, Fabiola ; Minisola, Giovanni ; Verna, Roberto</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c433t-47b772b348d1ae9c321c2b912f3ebcc56303e5e1236f95d597a293e3aab597753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adalimumab - blood</topic><topic>Adalimumab - immunology</topic><topic>Adalimumab - therapeutic use</topic><topic>Antibodies, Monoclonal - blood</topic><topic>Antibodies, Monoclonal - immunology</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Biological Factors - blood</topic><topic>Biological Factors - immunology</topic><topic>Biological Factors - therapeutic use</topic><topic>Biosimilar Pharmaceuticals - blood</topic><topic>Biosimilar Pharmaceuticals - therapeutic use</topic><topic>Drug Monitoring</topic><topic>Humans</topic><topic>Review</topic><topic>병리학</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Benucci, Maurizio</creatorcontrib><creatorcontrib>Grossi, Valentina</creatorcontrib><creatorcontrib>Manfredi, Mariangela</creatorcontrib><creatorcontrib>Damiani, Arianna</creatorcontrib><creatorcontrib>Infantino, Maria</creatorcontrib><creatorcontrib>Moscato, Paolo</creatorcontrib><creatorcontrib>Cinquanta, Luigi</creatorcontrib><creatorcontrib>Gremese, Elisa</creatorcontrib><creatorcontrib>Tolusso, Barbara</creatorcontrib><creatorcontrib>Petricca, Luca</creatorcontrib><creatorcontrib>Fedele, Anna Laura</creatorcontrib><creatorcontrib>Alivernini, Stefano</creatorcontrib><creatorcontrib>Atzeni, Fabiola</creatorcontrib><creatorcontrib>Minisola, Giovanni</creatorcontrib><creatorcontrib>Verna, Roberto</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Korean Citation Index</collection><jtitle>Annals of laboratory medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Benucci, Maurizio</au><au>Grossi, Valentina</au><au>Manfredi, Mariangela</au><au>Damiani, Arianna</au><au>Infantino, Maria</au><au>Moscato, Paolo</au><au>Cinquanta, Luigi</au><au>Gremese, Elisa</au><au>Tolusso, Barbara</au><au>Petricca, Luca</au><au>Fedele, Anna Laura</au><au>Alivernini, Stefano</au><au>Atzeni, Fabiola</au><au>Minisola, Giovanni</au><au>Verna, Roberto</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Laboratory Monitoring of Biological Therapies in Rheumatology: The Role of Immunogenicity</atitle><jtitle>Annals of laboratory medicine</jtitle><addtitle>Ann Lab Med</addtitle><date>2020-03-01</date><risdate>2020</risdate><volume>40</volume><issue>2</issue><spage>101</spage><epage>113</epage><pages>101-113</pages><issn>2234-3806</issn><eissn>2234-3814</eissn><abstract>Biological drugs, such as proteins and immunogens, are increasingly used to treat various diseases, including tumors and autoimmune diseases, and biological molecules have almost completely replaced synthetic drugs in rheumatology. Although biological treatments such as anti-tumor necrosis factor (TNF) drugs seem to be quite safe, they cause some undesirable effects, such as the onset of infections due to weakening of the immune system. Given the biological nature of these drugs, they might be recognized as extraneous; this would induce an immune reaction that neutralizes their effectiveness or lead to more serious consequences. Laboratories play a pivotal role in appropriate therapeutic management. The aim of this review was to underline the production of anti-drug antibodies during treatment with biological drugs and highlight the role of laboratories in ensuring appropriate use of these drugs.</abstract><cop>Korea (South)</cop><pub>The Korean Society for Laboratory Medicine</pub><pmid>31650726</pmid><doi>10.3343/alm.2020.40.2.101</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0001-9148-1548</orcidid><orcidid>https://orcid.org/0000-0001-8180-6660</orcidid><orcidid>https://orcid.org/0000-0002-9108-6609</orcidid><orcidid>https://orcid.org/0000-0003-3544-3162</orcidid><orcidid>https://orcid.org/0000-0003-4702-7094</orcidid><orcidid>https://orcid.org/0000-0001-6327-0874</orcidid><orcidid>https://orcid.org/0000-0003-2817-4822</orcidid><orcidid>https://orcid.org/0000-0002-8980-5141</orcidid><orcidid>https://orcid.org/0000-0002-2287-3027</orcidid><orcidid>https://orcid.org/0000-0001-9242-2793</orcidid><orcidid>https://orcid.org/0000-0002-1869-3912</orcidid><orcidid>https://orcid.org/0000-0002-7383-4212</orcidid><orcidid>https://orcid.org/0000-0002-2248-1058</orcidid><orcidid>https://orcid.org/0000-0002-9328-3075</orcidid><orcidid>https://orcid.org/0000-0002-6200-4467</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2234-3806
ispartof Annals of Laboratory Medicine, 2020, 40(2), , pp.101-113
issn 2234-3806
2234-3814
language eng
recordid cdi_nrf_kci_oai_kci_go_kr_ARTI_6867396
source PubMed Central
subjects Adalimumab - blood
Adalimumab - immunology
Adalimumab - therapeutic use
Antibodies, Monoclonal - blood
Antibodies, Monoclonal - immunology
Antibodies, Monoclonal - therapeutic use
Arthritis, Rheumatoid - drug therapy
Biological Factors - blood
Biological Factors - immunology
Biological Factors - therapeutic use
Biosimilar Pharmaceuticals - blood
Biosimilar Pharmaceuticals - therapeutic use
Drug Monitoring
Humans
Review
병리학
title Laboratory Monitoring of Biological Therapies in Rheumatology: The Role of Immunogenicity
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T13%3A08%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_nrf_k&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Laboratory%20Monitoring%20of%20Biological%20Therapies%20in%20Rheumatology:%20The%20Role%20of%20Immunogenicity&rft.jtitle=Annals%20of%20laboratory%20medicine&rft.au=Benucci,%20Maurizio&rft.date=2020-03-01&rft.volume=40&rft.issue=2&rft.spage=101&rft.epage=113&rft.pages=101-113&rft.issn=2234-3806&rft.eissn=2234-3814&rft_id=info:doi/10.3343/alm.2020.40.2.101&rft_dat=%3Cproquest_nrf_k%3E2309481263%3C/proquest_nrf_k%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c433t-47b772b348d1ae9c321c2b912f3ebcc56303e5e1236f95d597a293e3aab597753%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2309481263&rft_id=info:pmid/31650726&rfr_iscdi=true